Elevated Rates of Ventilator-Associated Pneumonia and COVID-19 Associated Pulmonary Aspergillosis in Critically Ill Patients with SARS-CoV2 Infection in the Second Wave: A Retrospective Chart Review
Open Access
- 7 May 2022
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 11 (5) , 632
Abstract
Due to multiple risk factors, the rate of ventilator-associated pneumonia in critically ill COVID-19 patients has been reported in a range of 7.6% to 86%. The rate of invasive pulmonary aspergillosis in this cohort has been reported at 4% to 30%. We undertook a retrospective chart review of 276 patients who were admitted to intensive care in a large university hospital. The period studied included patients from 23 February 2014 to 12 May 2021. Four groups were collected: COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia. Clinical characteristics, outcomes, and microbiological cultures were recorded. The incidence of ventilator-associated pneumonia in COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia was 5.45%, 27.40%, 16.67%, and 3.41%, respectively (p < 0.001). The rate of invasive pulmonary aspergillosis was 0%, 9.59%, 13.33%, and 6.82%, respectively (p < 0.001). A significantly elevated rate of ventilator-associated pneumonia and invasive pulmonary aspergillosis was noted in the second wave of COVID-19 when compared to the first. This was accompanied by an increase in the mortality rate. Increased steroid use was an independent risk factor for ventilator-associated pneumonia and invasive pulmonary aspergillosis across all four groups. Despite an increased understanding of this disease, no clinical trials have shown any promising therapeutic options at present.Keywords
This publication has 49 references indexed in Scilit:
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCell Host & Microbe, 2020
- Cytokine release syndrome in severe COVID-19Science, 2020
- Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammationIntensive Care Medicine, 2020
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research ConsortiumClinical Infectious Diseases, 2019
- Nosocomial Infections During Extracorporeal Membrane Oxygenation: Incidence, Etiology, and Impact on Patients’ OutcomeCritical Care Medicine, 2017
- A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unitJournal of Critical Care, 2017
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClinical Infectious Diseases, 2016
- Understaffing, overcrowding, inappropriate nurse:ventilated patient ratio and nosocomial infections: which parameter is the best reflection of deficits?Journal of Hospital Infection, 2012
- Galactomannan in Bronchoalveolar Lavage FluidAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated PneumoniaAnnals of Internal Medicine, 2000